ACW Ann: First patient treated in XanaCIDD Phase 2 Depression Trial - 8th Dec 2022, 1:29pm

annb0t

annb0t

Top 20
ACW Ann: First patient treated in XanaCIDD Phase 2 Depression Trial
Price Sensitive: Y
Date: 8th Dec 2022, 1:29pm

>>> Read announcement: Google: ACW Market Announcements
 
You must log in or register to reply here.

Similar threads

annb0t
ACW Ann: Amendment to Actinogen 2023 AGM resolutions 6 to 10 - 27th Oct 2023, 1:59pm
Replies
0
Views
160
annb0t
annb0t
annb0t
ACW Ann: ACW CMO presents academic poster at CTAD 2023 conference - 25th Oct 2023, 8:22am
Replies
0
Views
128
annb0t
annb0t
annb0t
ACW Ann: ACW CEO presentation for meetings at BIO Investor Forum USA - 18th Oct 2023, 8:57am
Replies
0
Views
126
annb0t
annb0t
annb0t
ACW Ann: Actinogen September quarterly activity report & Appendix 4C - 16th Oct 2023, 9:31am
Replies
0
Views
130
annb0t
annb0t
annb0t
ACW Ann: Annual Report to Shareholders - 13th Oct 2023, 11:26am
Replies
0
Views
156
annb0t
annb0t
Top Bottom